SUIT-2人胰腺癌细胞

SUIT-2细胞SUIT-2细胞SUIT-2；人胰腺癌细胞

Cell line name SUIT-2

Synonyms Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2

Accession CVCL_3172

Resource Identification Initiative To cite this cell line use: SUIT-2 (RRID:CVCL_3172)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Population: Japanese.

Doubling time: ~38.2 hours (PubMed=3102439); 29.1 hours (PubMed=1391733); 15.64 hours (JWGray panel).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.

Sequence variations

Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=11787853).

Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853; PubMed=21607521).

Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853; PubMed=21607521).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*02:06,24:02

HLA-B B*07:02,59:01

HLA-C C*01:02,07:02

Class II

HLA-DQ DQA1*02:01,02:01

DQB1*06:13,06:13

HLA-DR DRB1*11:04,15:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 1.31

East Asian, North 81.51

East Asian, South 17.16

South Asian 0.02

European, North 0

European, South 0

Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_B279 (S2-007) CVCL_B280 (S2-013) CVCL_B281 (S2-020)

CVCL_B282 (S2-028) CVCL_F971 (S2-CP8) CVCL_F972 (S2-VP10)

CVCL_B283 (S2/TXT)

Sex of cell Male

Age at sampling 73Y

Category Cancer cell line

STR profile Source(s): Cosmic-CLP=1240219; JCRB=JCRB1094; PubMed=25877200; TKG=TKG 0705

 

Markers:

Amelogenin X

CSF1PO 11,12

D3S1358 16

D5S818 11,12

D7S820 9,11

D8S1179 14,15

D13S317 9,11

D16S539 9

D18S51 16

D21S11 29,30

FGA 20,23

Penta D 11

Penta E 10

TH01 6

TPOX 8,10

vWA 16,17

 

Run an STR similarity search on this cell line

PubMed=3102439; DOI=10.20772/cancersci1985.78.1_54

Iwamura T., Katsuki T., Ide K.

Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9.

Jpn. J. Cancer Res. 78:54-62(1987)

 

PubMed=1391733; DOI=10.1111/j.1440-1746.1992.tb01030.x

Iwamura T., Taniguchi S., Kitamura N., Yamanari H., Kojima A., Hidaka K., Setoguchi T., Katsuki T.

Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2).

J. Gastroenterol. Hepatol. 7:512-519(1992)

 

PubMed=21607521; DOI=10.3892/or.1.6.1223

Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.

Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.

Oncol. Rep. 1:1223-1227(1994)

 

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C

Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.

Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.

Int. J. Cancer 91:350-358(2001)

 

PubMed=11787853; DOI=10.1007/s004280100474

Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Virchows Arch. 439:798-802(2001)

 

PubMed=11854916; DOI=10.3748/wjg.v7.i6.855; PMCID=PMC4695609

Liu B., Staren E., Iwamura T., Appert H., Howard J.

Taxotere resistance in SUIT. Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

World J. Gastroenterol. 7:855-859(2001)

 

PubMed=12800145; DOI=10.1002/gcc.10218

Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Genes Chromosomes Cancer 37:333-345(2003)

 

PubMed=19077451; DOI=10.1159/000178871

Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.

Genome-wide analysis of pancreatic cancer using microarray-based techniques.

Pancreatology 9:13-24(2009)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)